Table 1.
Classification, mitotic rate and survival times in cats treated for lymphoma
| Case | Anatomical classification | Mitoses/HPF | WHO classification | Treatment | OST (days) |
|---|---|---|---|---|---|
| 26 | Alimentary | 2.7 | PTCL | VELCAP | 681 |
| 22 | EN (laryngeal) | 3 | PTCL* | VELCAP, 6 × 4 Gy | 649 |
| 2 | EN (cutaneous) | 3.8 | PTCL* | COP + ELA, 5 × 4 Gy, 2 × 4 Gy | 259 |
| 7 | Alimentary | 2.4 | PTCL | sx, COP | 213 |
| 3 | Alimentary | 6.8 | PTCL | sx, prednisolone, 2 × 4 Gy | 201 |
| 1 | Nodal | 1.7 | PTCL | sx, COP + ELCyt | 183 |
| 17 | Alimentary | 7.7 | PTCL | sx, A | 163 |
| 4 | Alimentary | 8.2 | PTCL | sx, COP | 113 |
| 19 | EN (cutaneous) | 6 | PTCL | EL, 15 × 3.2 Gy | 56 |
| 9 | Alimentary | 2.5 | PTCL | COP + EL | 14 |
| 28 | Alimentary | 0.2 | PTCL* | VELCAP | 12 |
| 29 | Alimentary | 0 | DLBCL | COP + A | 355 |
| 11 | Nodal | 1.5 | DLBCL* | COP + ELACyt, 5 × 4, 2 × 4 Gy | 180 |
| 27 | EN (nasal) | 2 | DLBCL | VELCAP | 142 |
| 13 | EN (cutaneous) | 5.5 | DLBCL* | COP + A | 134 |
| 6 | EN (laryngeal) | 1 | DLBCL* | COP, 5 × 4 Gy | 66 |
| 23 | EN (nasal) | 0.9 | DLBCL* | VELCAP, 15 × 3.2 Gy | 63 |
| 14 | EN (nasal) | 3.4 | DLBCL* | COP + EL, 5 × 4 Gy, 3 × 4 Gy | 49 |
| 5 | M (nodal + renal) | 1.3 | TCRBCL | COP + EL | 746 † |
| 8 | Alimentary | 5.7 | TCRBCL | sx, COP + ACyt, 2 × 4 Gy, 2 × 4 Gy | 422 |
| 10 | EN (nasal) | 2.4 | TCRBCL | COP + A, 8 × 4 Gy | 152 |
| 20 | Alimentary | 0 | ITCL | sx, VELCAP | 796 |
| 30 | Alimentary | 0 | ITCL* | Chlorambucil + P | 625 † |
| 24 | Alimentary | 0 | ITCL* | VELCAP | 596 |
| 21 | Alimentary | 2.1 | T-LGL | sx, VELCAP | 455 |
| 25 | Alimentary | 8.3 | T-LGL | sx, VP | 19 |
| 16 | EN (cutaneous) | 2.3 | T-ALCL | sx, VELCAP | 190 |
| 18 | EN (cutaneous) | 3.2 | T-ALCL | sx, VELCAP | 36 |
| 12 | EN (ocular) | 5.2 | T-AL* | COP + EL, 3x3 Gy | 52 |
| 15 | EN (laryngeal) | 0 | B-SLL* | COP | 6 |
Pretreated with glucocorticoids
Still alive
EN = extranodal lymphoma; M = mixed lymphoma; HPF = high-power fields; WHO = World Health Organization; T = T-cell lymphoma; B = B-cell lymphoma; PTCL = peripheral T-cell lymphoma; DLBCL = diffuse large B-cell lymphoma; TCRBCL = T-cell-rich B-cell lymphoma; ITCL = intestinal T-cell lymphoma; LGL = large granular lymphocyte lymphoma; ALCL = anaplastic large cell lymphoma; AL = angiotropic lymphoma; SLL = small lymphocytic lymphoma; sx = cytoreductive surgery; V = vincristine; O = Oncovine; EL = Elspar (L-asparaginase); C = cyclophosphamide; A = Adriblastine (doxorubicin); P = prednisolone; Cyt = cytarabine; Gy = Gray; OST = overall survival time